津巴布韦哈拉雷2019年伤寒结合疫苗运动期间免疫接种后不良事件的强化监测
2019年2月25日至3月4日,津巴布韦在哈拉雷高风险郊区开展应急伤寒结合疫苗(TCV)接种,采用主动监测、被动监测和接种后覆盖调查三种方法捕获不良事件。主动监测发现39例不良事件,每10万剂次攻击率以惊厥(6.27)和超敏反应(5.02)最高;覆盖调查中177名(10%)受种者报告不良事件。强化监测支持TCV的安全性,多数事件轻微或恢复后无长期后遗症。
要点
- 主动监测发现39例不良事件,其中惊厥19例(16例为发热性)、超敏反应16例。
- 每10万剂次攻击率:惊厥6.27,超敏反应5.02。
- 覆盖调查1817名受种者中177名(10%)报告不良事件,其中25名(14%)寻求医疗。
核心结论
- 与既往TCV评估一致,应急接种期间的强化不良事件监测支持TCV的安全性,多数报告事件轻微或恢复后无长期后遗症。
- 惊厥和超敏反应攻击率低于此前在肯尼亚和布基纳法索开展的主动监测研究。
研究设计与样本
- 2019年2月25日至3月4日,津巴布韦卫生部在哈拉雷八个高风险郊区对6月龄至15岁人群、在一个郊区对至45岁人群开展应急TCV接种,使用342000剂次。
- 采用三种方法捕获接种期间及末次接种后42天内的不良事件:两家哈拉雷医院主动监测、国家被动监测、接种后覆盖调查。
主要发现
- 主动监测识别39例不良事件:惊厥19例(16例为发热性)、超敏反应16例、血小板减少症1例、过敏性休克1例、两种病症共存2例。
- 39例患者中仅21例(54%)住院,38例恢复后无后遗症。
- 每10万剂次TCV攻击率以惊厥(6.27)和超敏反应(5.02)最高。
- 被动监测中,两家主动监测医院以外的机构仅报告6例不良事件。
- 覆盖调查1817名受种者中177名(10%)报告不良事件,其中25名(14%)寻求医疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During February 25-March 4, 2019, Zimbabwe's Ministry of Health and Child Care conducted an emergency campaign using 342,000 doses of typhoid conjugate vaccine (TCV) targeting individuals 6 months-15 years of age in eight high-risk suburbs of Harare and up to 45 years of age in one suburb of Harare. The campaign represented the first use of TCV in Africa outside of clinical trials. METHODS: Three methods were used to capture adverse events during the campaign and for 42 days following the last dose administered: (1) active surveillance in two Harare hospitals, (2) national passive surveillance, and (3) a post-campaign coverage survey. RESULTS: Thirty-nine adverse events were identified during active surveillance, including 19 seizure cases (16 were febrile), 16 hypersensitivity cases, 1 thrombocytopenia case, 1 anaphylaxis case, and two cases with two conditions. Only 21 (54%) of 39 patients were hospitalized and 38 recovered without sequelae. Attack rates per 100,000 TCV doses administered were highest for seizures (6.27) and hypersensitivity (5.02). Only 6 adverse events were reported through passive surveillance by facilities other than the two active surveillance hospitals. A total of 177 (10%) of 1,817 vaccinees surveyed reported experiencing an adverse event during the post-campaign coverage survey, of which 25 (14%) sought care. CONCLUSIONS: In line with previous evaluations of TCV, enhanced adverse event monitoring during an emergency campaign supports the safety of TCV. The majority of reported events were minor or resulted in recovery without long-term sequelae. Attack rates for seizures and hypersensitivity were low compared with previous active surveillance studies conducted in Kenya and Burkina Faso. Strengthening adverse event monitoring in Zimbabwe and establishing background rates of conditions of interest in the general population may improve future safety monitoring during new vaccine introductions.
引用
- Shaum A, Mujuru HA, Takamiya M, et al. Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe. Vaccine. 2022. PMID: 35568590. doi:10.1016/j.vaccine.2022.04.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。